TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00622648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin
Description: 40 mg once daily for 6 to 14 days (10 ± 4 days)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
Study: NCT02195752

Intervention type: OTHER
Intervention: Compounded Pain Cream
Description: All patients will have been prescribed a topical pain cream prepared by a qualified compounding pharmacy
Study: NCT03964961

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional massage
Description: It's a massage combined with a stretching of the muscles.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional massage
Description: It's a regular massage made with the therapist's hands.
Study: NCT02187471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Description: DS-5565 15 mg QD or BID; tablet for oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DS-5565
Description: DS-5565 15 mg QD or BID; tablet for oral use

Intervention type: DRUG
Group type: OTHER
Intervention: Pregabalin
Description: Pregabalin capsule for oral use; 75 mg capsule for one week, then 150 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: Placebo tablet for oral use, matching DS-5565 tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo tablet for oral use, matching DS-5565 tablet

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo tablet
Description: Placebo tablet for oral use, matching DS-5565 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsule for oral use, matching pregabalin capsule
Study: NCT03667287

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Repair of parastomal hernia
Description: Surgical repair of symptomatic parastomal hernia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Repair of parastomal hernia
Description: Surgical repair of symptomatic parastomal hernia.
Study: NCT02187471

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo capsule
Description: Placebo capsule for oral use, matching pregabalin capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsule
Description: Placebo capsule for oral use, matching pregabalin capsule
Study: NCT01925417

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RBX2660 (microbiota suspension)
Study: NCT03320811

Intervention type: OTHER
Intervention: Data record

Intervention type: OTHER
Intervention: Data record
Study: NCT04945811

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Interlukein 6 and procalcitonin serum levels
Description: Blood tests
Study: NCT01147458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04191834
Description: 100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04191834 placebo
Description: Matching PF-04191834 placebo tablets to be administered BID for two weeks
Study: NCT01492608

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulphate
Description: Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium sulphate
Description: Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.
Study: NCT01147458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen placebo
Description: Matching naproxen placebo tablets to be administered BID for 4 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04191834 placebo
Description: Matching PF-04191834 placebo tablets to be administered BID for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04191834
Description: 100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
Study: NCT03846752

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: radial artery access for complex PCI
Description: Complex PCI with access via radial artery using a 7 Fr. Glideslender sheath. PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: femoral artery access for complex PCI
Description: Complex PCI with access via femoral artery using a 7 Fr. standard femoral sheath . PCI will be performed according to standard procedures and left to the discretion of the operator, however in case of stent placement the use of Ultimaster stents (Terumo) are highly recommended.
Study: NCT05069246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nigella Sativa oil
Description: 5ml Nigella Sativa oil mixed into 5ml water prior to use and rinsed in the mouth for 3 mins and spitted out, used twice a day; morning and evening.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chlorhexidine mouthwash
Description: 10ml of chlorohexidine mouthwash used for 3mins and spit out, used twice a day; morning and evening.
Study: NCT02177968

Intervention type: OTHER
Intervention: descriptive analysis of characteristics
Description: comparison between elderly fallers and non-fallers
Study: NCT00082888

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tipifarnib
Description: Given PO
Study: NCT01263171

Intervention type: DRUG
Group type: OTHER
Intervention: Leucovorin

Intervention type: DRUG
Group type: OTHER
Intervention: fluorouracil

Intervention type: DRUG
Group type: OTHER
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: OTHER
Intervention: oxaliplatin

Intervention type: PROCEDURE
Group type: OTHER
Intervention: adjuvant therapy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: neoadjuvant therapy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: therapeutic conventional surgery

Intervention type: RADIATION
Group type: OTHER
Intervention: radiation therapy
Study: NCT01147458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen placebo
Description: Matching naproxen placebo tablets to be administered BID for 4 weeks
Study: NCT03344315

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: experimental: collagen matrix
Description: Mucograft collagen matrix combined with coronal advanced flap

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: autologous connective tissue graft
Description: Soft tissue harvesting from patient palate with coronal advanced flap
Study: NCT03841071

Intervention type: OTHER
Intervention: ROM/CFS intervention
Description: The intervention (ROM/CFS) includes self-reported measures for adaptation to life with an ostomy and health-related quality of life, as well as patient satisfaction recorded by the clinical feedback system. The measures are electronically assessed before each clinical consultation at 3, 6, and 12 months after surgery, and annually thereafter. The scores are instantly analysed and graphically presented for use during the consultation and the patient and stoma care nurse can discuss the findings.
Study: NCT00286273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trisodium citrate
Description: for regional anticoagulation of the extracorporeal CVVH circuit
Study: NCT01147458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04191834
Description: 100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 500 mg tablet administered BID for a total of four weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04191834 placebo
Description: Matching PF-04191834 placebo tablets to be administered BID for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naproxen
Description: Naproxen 500 mg tablet administered BID for a total of four weeks
Study: NCT00286273

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nadroparin
Description: for anticoagulation of the extracorporeal CVVH circuit
Study: NCT03303950

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hematopoietic Cell Transplantation
Description: Undergo HSCT

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT03652532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alternate Day Fasting
Description: During the 8-week intervention, participants consumed 25% of their daily recommended energy intake (approximately 500 kcal) on each fast day (24 h), and consumed food ad libitum on each feed day (24 h). The fast day and feed day were repeated every other day, and the fast day occurred 3 days per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Alternate Day Fasting
Description: During the 8-week intervention, participants consumed 25% of their daily recommended energy intake (approximately 500 kcal) on each fast day (24 h), and consumed food ad libitum on each feed day (24 h). The fast day and feed day were repeated every other day, and the fast day occurred 3 days per week.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: During the 8-week intervention, participants visited the research center gym at least three times per week and received exercise logs. Each exercise session began with 5 minutes of warm-up and ended with 5 minutes of cool-down. Resistance training was performed using weight training machines, barbells, and dumbbells for 40 minutes. Aerobic exercise was performed on motorized treadmills for 20 minutes.
Study: NCT01147458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04191834 placebo
Description: Matching PF-04191834 placebo tablets to be administered BID for two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04191834
Description: 100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
Study: NCT02967575

Intervention type: DEVICE
Intervention: cTDR
Description: The surgical procedure for the Triadyme-C total disc replacement corresponds to the standard surgical technique for cTDR:~* Implantation through a standard anterior cervical approach~* Midline identification~* Routine discectomy with endplate preparation and decompression~* Implant sizing and trial implantation~* Keel preparation~* Implant preparation and loading of the appropriate Triadyme-C implant~* Triadyme-C insertion, positioned as close to the midline as possible
Study: NCT06381232

Intervention type: OTHER
Intervention: No Intervention
Description: This is an observational study, there are no interventions.

Intervention type: OTHER
Intervention: No Intervention
Description: This is an observational study, there are no interventions.
Study: NCT03829384

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA-1944
Description: mRNA encoding Chikungunya antibody

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT03550209

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCPUFA Oil Supplement
Description: 25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCPUFA Oil Supplement
Description: 25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCPUFA Oil Supplement
Description: 25 mg/kg, 50 mg/kg, or 75 mg/kg of GLA+EPA+DHA as Omega 3-6 oil to be administered twice per day by mouth for 90 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Canola Oil Placebo
Description: Equal volume (25 mg/kg, 50 mg/kg, or 75 mg/kg) of placebo (canola) oil to be administered twice per day by mouth for 90 days
Study: NCT03652532

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: During the 8-week intervention, participants visited the research center gym at least three times per week and received exercise logs. Each exercise session began with 5 minutes of warm-up and ended with 5 minutes of cool-down. Resistance training was performed using weight training machines, barbells, and dumbbells for 40 minutes. Aerobic exercise was performed on motorized treadmills for 20 minutes.
Study: NCT05504954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IMARA-SA (intervention group)
Description: The IMARA-SA intervention aligns with an ecological framework, emphasizing the intersection of individual, social, and structural determinants of women's sexual health and behavior. Separate FC and AGYW groups run simultaneously and cover parallel content, while joint activities enhance FC credibility as a resource for HIV/STI prevention and facilitate practice of communication skills. Interventionists use interactive and experiential activities. IMARA-SA's goals and motto emphasize strong FC-AGYW relationships, sisterhood, community empowerment, and motivation for HIV prevention, and build group cohesion. FC and AGYW sign a pact to confirm commitment to the program. At the end of Workshop Day 1, participants receive homework to complete during the week. Woven throughout IMARA-SA is the impact of mental health issues, alcohol and drug use, and violence on HIV-risk.
Study: NCT02555878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban 10 milligram (mg) tablet will be administered orally once daily for 180 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo tablet will be administered orally once daily for 180 days.
Study: NCT03024372

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AV Fistula creation with sutures
Description: End-to-side anastomosis (of AV fistula) is to be constructed using sutures. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AV Fistula creation with clips
Description: End-to-side anastomosis (of AV fistula) is to be constructed using clips. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.
Study: NCT05504954

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health promotion control group
Description: The health promotion control intervention is a family-based intervention previously delivered to families in SA and translated into isiXhosa. The intervention promotes healthy living by encouraging good nutrition, exercise, and violence reduction. It will be delivered in the same format as IMARA and will be identical in length and intensity.
Study: NCT02390011

Intervention type: PROCEDURE
Intervention: MRI
Study: NCT02289222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3475
Description: Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.
Study: NCT00594139

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous neobladder construct
Description: provision of an autologous neo-bladder construct
Study: NCT01009567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabergoline
Description: Receive cabergoline tablet (0/5 mg) daily until 6 days after oocytes retrieval

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control
Description: Receive human albumin 20% infusion
Study: NCT02289222

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pomalidomide
Description: Pomalidomide is given at standard dose of 4 mg daily orally for 21 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone is given at 40 mg orally weekly
Study: NCT03724565

Intervention type: PROCEDURE
Intervention: Method of endoscopic procedure
Description: Air quality according to the method of endoscopic procedure will be checked (for example, upper diagnostic endoscopy, colonoscopy, endoscopic submucosal dissection, endoscopic mucosal resection, etc)
Study: NCT05267457

Intervention type: OTHER
Intervention: Plasma vanadium concentration
Description: Plasma vanadium concentrations were measured using inductively coupled plasma mass spectrometry (ICP-MS) (Agilent 7700 Series, United States)
Study: NCT01725555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasted treatment: AXL1717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fasted treatment: AXL1717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fed treatment: AXL1717

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fed treatment: AXL1717
Study: NCT03785990

Intervention type: OTHER
Intervention: adipose tissue
Description: taking a sample of the adipose tissue during operation

Intervention type: OTHER
Intervention: adipose tissue
Description: taking a sample of the adipose tissue during operation
Study: NCT00594243

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based stress reduction program
Description: 8-week mindfulness based stress reduction program

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Wait-list control
Description: No treatment given.
Study: NCT03785990

Intervention type: OTHER
Intervention: adipose tissue
Description: taking a sample of the adipose tissue during operation
Study: NCT02852616

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Narrative Exposure Therapy
Description: 8 - 15 sessions: 1 lifeline session, 5 - 12 sessions narrative exposure, 1-2 sessions of future-oriented counselling
Study: NCT03785990

Intervention type: OTHER
Intervention: blood
Description: taking a blood sample when a peripheral venous catheter is inserted before operation

Intervention type: OTHER
Intervention: blood
Description: taking a blood sample when a peripheral venous catheter is inserted before operation

Intervention type: OTHER
Intervention: blood
Description: taking a blood sample when a peripheral venous catheter is inserted before operation

Intervention type: DIAGNOSTIC_TEST
Intervention: PEAPOD
Description: Measurement of the total adipose tissue of the infant with PEAPOD (Air Displacement-Plethysmography, Infant Body Composition System, Cosmed, Rome, Italy)

Intervention type: DIAGNOSTIC_TEST
Intervention: PEAPOD
Description: Measurement of the total adipose tissue of the infant with PEAPOD (Air Displacement-Plethysmography, Infant Body Composition System, Cosmed, Rome, Italy)

Intervention type: DIAGNOSTIC_TEST
Intervention: PEAPOD
Description: Measurement of the total adipose tissue of the infant with PEAPOD (Air Displacement-Plethysmography, Infant Body Composition System, Cosmed, Rome, Italy)
Study: NCT00756145

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: At start of the session, at the inlet line
Description: Injection of LMWH at the inlet line, at the start of the hemodiafiltration session

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 5 minutes after the start of the session, at the inlet line
Description: Injection of LMWH at the inlet line, 5 minutes after the start of the hemodiafiltration session

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: At the start of the session, at the outlet line
Description: Injection of LMWH at the outlet line, at the start of the hemodiafiltration session
Study: NCT01135498

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eloxatin
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine [Xeloda]
Description: Oral repeating dose
Study: NCT00589264

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc
Description: 10 mg elemental zinc + 10 mg elemental iron + 0.5 mg copper syrup taken daily for 1 year, from 6 to 18 months of age

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: iron + copper
Description: 10 mg elemental iron + 0.5 mg copper in syrup given daily for one year from 6 months to 18 months of age
Study: NCT02399020

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Cognition and Interaction Training
Description: manualized group treatment providing training in facial emotion recognition, understanding the role of emotion in social situations, training with videoed vignettes to avoid jumping to conclusions in order to avoid attributional biases, tolerating ambiguity and distinguishing facts from guesses, skill consolidation and generalization to everyday life situations.
Study: NCT03160170

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SISTER device
Description: Use of the Suction-Integrated Surgical Tissue Elevator \& Retractor (SISTER) device during surgery
Study: NCT02247544

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Trabectedin administered at a dose of 1.5 mg/m2 - 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access until progressive disease, major toxicity, patient's intolerance, unwillingness to continue treatment, or medical decision by the responsible physician